

# Top 10 US Ideas Quarterly

## Introducing the Top 10 US Ideas for Q2 2025

Strategy

### Nine Longs and One Short

We present our new list of ten short-term stock recommendations among US stocks under coverage based on our view that these stocks could have significant market and business-related catalysts in the quarter ahead. For 2Q25 our Top 10 Ideas include nine Buys and one Underperform across nine industries. Our Buys are Agnico Eagle Mines, AMETEK, Bath & Body Works, Eli Lilly, Energy Transfer LP, Goldman Sachs, Ralph Lauren, RenaissanceRe, and The Trade Desk. Our Underperform is Hims & Hers Health.

### Ready or not, here they come

Uncertainty around potential tariff announcements slated for April 2<sup>nd</sup> dominates market headlines. Our Economics team expects a combination of [reciprocal and sector-specific tariffs](#) with a base case of a 5pp increase in effective tariffs vs. pre-election. While our Strategy team estimates [a realistic bad case](#) could result in a 10% hit to S&P EPS.

### How this list will be maintained and updated

We will publish this list at the beginning of each quarter. Ideas will generally remain on the list through the quarter unless coverage is dropped or the rating changes. Any security that is removed will not be replaced. If there are changes to the list during the quarter, we will publish the change in a research report. Securities are intended to stay on the list for one quarter, although some may be chosen for the next quarter's list. We will publish performance quarterly.

**Table 1: Top 10 US Ideas List – 2Q25**

High-conviction, short-term stock recommendations for the quarter ahead

Company	Ticker	Analyst	Rating	Rec	Price	PO	Mkt Cap (mn)
Agnico Eagle	AEM	Winder,Lawson	B-1-7	BUY	\$108.41	\$119	\$52,682.64
AMETEK	AME	Obin,Andrew	B-1-7	BUY	\$172.14	\$225	\$42,948.32
Bath & Body Works	BBWI	Hutchinson, Lorraine	C-1-7	BUY	\$30.32	\$45	\$9,789.78
Eli Lilly	LLY	Timothy	B-1-7	BUY	\$825.91	\$1,000	\$826,255.90
Energy Transfer LP	ET	Salisbury,Jean Ann	B-1-7	BUY	\$18.59	\$23	\$68,789.59
Goldman Sachs	GS	Poonawala, Ebrahim	B-1-7	BUY	\$546.29	\$700	\$250,683.07
Ralph Lauren	RL	Nardone, Christopher	B-1-7	BUY	\$220.74	\$318	\$18,276.60
RenaissanceRe	RNR	Shanker,Joshua	B-1-7	BUY	\$240.00	\$426	\$11,717.90
The Trade Desk	TTD	Reif Ehrlich, Jessica	C-1-9	BUY	\$54.72	\$130	\$54,961.33
Hims & Hers	HIMS	Lutz,Allen	C-3-9	UNDERPERFORM	\$29.55	\$22	\$7,084.93

**Source:** BofA Global Research, Bloomberg

BofA GLOBAL RESEARCH

01 April 2025

Equity

United States

**Alpha Generation Research**  
BofAS

**Anthony Cassamassino**  
Strategist  
BofAS  
+1 212 449 6874  
anthony.cassamassino@bofa.com

See Team Page for List of Analysts

Trading ideas and investment strategies discussed herein may give rise to significant risk and are not suitable for all investors. Investors should have experience in relevant markets and the financial resources to absorb any losses arising from applying these ideas or strategies.

**BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.**

**Refer to important disclosures on page 29 to 32. Analyst Certification on page 21. Price Objective Basis/Risk on page 19.**

# Agnico Eagle Mines (AEM)

**Lawson Winder, CFA >>**

Research Analyst

Merrill Lynch (Canada)

+1 416 369 7592

lawson.winder@bofa.com


## Buy, \$119 PO

### 2Q investment thesis

BofAe Global Research is bullish on the gold price, calling for it to reach \$3,500/oz within the next two years, assuming investment demand increases by 10% (see the report: [Updated BofA gold price outlook 26-Mar-25](#)). Near-term, tariff and geopolitical risk could keep upward pressure on the gold price, as should buying from the Chinese insurance industry, central banks, and retail investors. We see Agnico Eagle Mines (AEM) as the ideal vehicle for gaining that exposure. We think AEM has the best management and management structure in the gold sector (and is among the top managements in metals & mining generally), the company's assets are primarily located in the top mining jurisdictions globally (Australia, Canada, Finland), the AEM portfolio contains significant extension and expansion potential, and with the gold price (at \$3,125/oz) well above the 2025 Bloomberg consensus forecast of \$2,762/oz, we think there is upside risk to Street earnings estimates.

#### Exhibit 1: 2025E consolidated production by country

On our estimates, Canada accounts for a majority of 2025E consolidated production (at ~84%).




Source: BofA Global Research

BofA GLOBAL RESEARCH

#### Exhibit 2: 2025E NAV by country

Canada is the largest geographic driver of our 2025E NAV for AEM, accounting for 89% of the total NAV.



Source: BofA Global Research

BofA GLOBAL RESEARCH

Our \$119 per share price objective is based on Agnico Eagle trading at 2.5x times our estimated NAV (current net debt position plus a mining asset DCF utilizing a 5% WACC). Historically, North American gold producers have traded between 1 and 3 times NAV, with higher multiples being accorded to the organically growth-oriented gold producers, located in strong jurisdictions, and with a history of strong execution, those like AEM.

#### Table 2: Agnico Eagle Mines key stock data

We highlight AEM as a top Q1'25 stock idea

Industry		North American Metals & Mining	
Market Cap (mn)		\$52,682.64	
Price		\$108.41	
P/E (2025)		21.3x	
% of sell-side rated Buy		83%	
Short interest % of float		1.52%	

Source: BofA Global Research estimates, Bloomberg

BofA GLOBAL RESEARCH



**Catalysts:**

The gold price: Where could demand come from? China's insurance industry can invest 1% of its assets in gold, equivalent to around 6% of the annual gold market. Central banks (CB) currently hold about 10% of their reserves in gold, and could raise this figure to +30% to make their portfolios more efficient. Finally, retail investors have also been increasing their exposure to the yellow metal, with assets under management at physically backed ETFs increasing by 4% YoY YTD in the Americas, Europe and Asia. Uncertainty around Trump Administration trade policies could continue to push the USD lower, further supporting gold prices near-term.

Earnings estimate updates: With the gold price (at \$3,125/oz) well above the 2025 Bloomberg consensus forecast of \$2,762/oz, there is upside risk to Street earnings estimates. We estimate that for every \$100/oz change in the gold price, our EBITDA, EPS and free cash flow estimates for AEM change by \$334m (6%), \$0.44 (9%), and \$333m (15%). We also note that AEM has a track record of consistently meeting but often beating the mid-point of their annual guidance ranges, suggesting the possibility for estimate upside beyond the rising gold price.

Exploration updates: AEM has a long and proud tradition of exploration success leading to both significant mining asset life extensions and driving the justification for significant expansions in the annual production from its mining assets. In its portfolio, there are several key assets that have delivered news meaningful exploration success on a regular, often quarterly basis, these include the Canadian Malartic/Odyssey gold complex in Québec, the Hope Bay gold project in Nunavut, and the Detour Lake gold mining operation in Ontario, to name a few.

**BofA Global Research Reports**

<b>Title: Subtitle</b>	<b>Primary Author</b>	<b>Date Published</b>
<a href="#">North American Precious Metals Weekly: Gold price leverage: who's exposed most to up (and down)-side to gold price changes?</a>	Lawson Winder, CFA	16 March 2025
<a href="#">North American Precious Metals Weekly: Preliminary 2024 gold reserve analysis shows a 13% higher average reserve life</a>	Lawson Winder, CFA	03 March 2025
<a href="#">Agnico Eagle Mines: Q4'24 EPS beat and guidance in-line. Focus remains on cost control, capital discipline.</a>	Lawson Winder, CFA	14 February 2025
<a href="#">North American Metals &amp; Mining: Year Ahead 2025: CCJ, IVN, AEM, STLD are top picks across the sub-sectors</a>	Lawson Winder, CFA	06 January 2025

**Upside risks:** Upside risks to our PO are: 1) a higher than forecast gold price, 2) exploration success, 3) local currency weakness vs. the USD that reduces USD operating costs, and 4) better than guided and/or forecast operating and financial results.

**Downside risks:** 1) A lower than forecast gold price, 2) geological or technical issues at mine sites, 3) local currency strength vs. the USD that increases USD operating costs, and 4) operation or financial results that miss forecasts and/or guidance.

**Company Description:** Agnico Eagle is a senior gold mining company with multiple operating mines located in Canada, Finland, Australia and Mexico. AEM follows a "district" operating model, referring to the fact that AEM's asset base is highly regionalized. This gives the company the flexibility to leverage infrastructure, capital-intensive equipment, and skilled labor across multiple assets over the long-term. In doing so, we think the company could spread fixed costs over a larger volume of production, leading to economies of scale via lower unit costs and increased operating efficiencies.



# Ametek (AME)

## Andrew Obin

Research Analyst

BofAS

+1 646 855 1817

[andrew.obin@bofa.com](mailto:andrew.obin@bofa.com)

## Buy, PO \$225

### 2Q investment thesis

We expect Ametek 2025 earnings estimates to be revised upwards following 1Q25 results. Our \$7.30 adjusted EPS estimate is \$0.17 above \$7.13 consensus.

In 2024, Ametek saw varied trends across its end markets. Aerospace (18% of revenue) and Power (12% of revenue) segments had steady revenue growth of 5% y/y. Process & Analytical Instrumentation (47% of revenue) had flattish revenue. What drove the (2)% overall organic revenue decline was customer destocking in the Automation & Engineered Solutions segment (23% of revenue).

Ametek sells niche components to original equipment manufacturers. This gives the company strong pricing power, but with short-cycle exposure. Ametek's Automation & Engineered Solutions products include motion control equipment, electrical connectors, motors, pumps, and heat exchangers, as well as single-use surgical instruments and implantable components.

Broader leading indicators of demand, such as the US manufacturing PMI and OECD US leading indicators have turned up. These historically have had a good correlation with Ametek's organic revenue growth with a two-quarter lag.

We base our \$225 price objective on a 20x EV/EBITDA multiple of our 2026 estimates. Our target multiple is a premium to the 19x peer average on 2025E, reflecting above-peer margins and track record of capital deployment.

### Table 3: Ametek key stock data

We highlight AME as a 2Q25 top pick

Industry	Multi-industry
Market Cap (mn)	\$42,948.32
Price	\$172.14
P/E (2025)	23.3x
% of sell-side rated Buy	71%
Short interest % of float	1.3%

Source: BofA Global Research estimates, Bloomberg

BofA GLOBAL RESEARCH

### Catalysts:

Lapping destocking: As mentioned above, Ametek saw a significant drag from destocking, particularly in Automation & Engineered Solutions. Organic orders accelerated to +4% y/y from +2% last quarter despite an 800bp tougher comparison, suggesting we are finally through the destocking. The combination of improving leading indicators and easier comparisons (due to the destocking impact) could drive better-than-expected organic revenue growth in 1Q and beyond.

Building Paragon Medical synergies: Ametek closed on the \$1.9bn acquisition of Paragon Medical in December 2023, the largest in the company's history. Management expects



to reach \$70mn run-rate integration savings over time. We estimate this could be a \$16mn y/y benefit, or 1% earnings tailwind in 2025. In 4Q24, Paragon Medical saw a double-digit sequential increase in orders.

**Upside from potential M&A:** Over the past five years, Ametek has averaged \$1.2bn per year on acquisitions. However, 2024 was a period of low activity (\$0.1bn). In January 2025, Ametek closed on the acquisition of Kern Microtechnik for ~\$109mn. Based in Germany, Kern manufactures high-precision machining equipment and generates EUR 50mn of annual revenues. CEO Zapico is optimistic on the M&A pipeline. Historically, AME shares have responded positively to deal announcements.

**Earnings results (estimated early May):** For 1Q25, we forecast flat revenue growth and 10bp of y/y operating margin expansion. This translates to \$1.69 in adjusted EPS. For 2025, we forecast 3% y/y revenue growth and 80bp of y/y operating margin expansion, implying ~50% incremental margin. Our \$7.30 adjusted EPS (+7% y/y) is \$0.17 above consensus.

#### BofA Global Research Reports

Title: Subtitle	Primary Author	Date Published
<a href="#">Industrials/Multi-Industry: Manufacturing capex getting another boost</a>	Andrew Obin	04 March 2025
<a href="#">AMETEK Inc: Orders accelerate in 4Q24, but initial '25 guide is conservative</a>	Andrew Obin	04 February 2025
<a href="#">AMETEK Inc: Upgrade to Buy, cyclical turn ahead</a>	Andrew Obin	16 December 2024

**Upside risks:** Upside risks to our price objective are: 1) secular growth in automation and aerospace end markets, 2) accretive acquisitions, and 3) share gains for differentiated products.

**Downside risks:** Downside risks to our price objective are: 1) weaker industrial production trends, 2) slower pace of acquisitions, and 3) cyclical risks on shorter cycle component businesses.

**Company Description:** Ametek Inc. (AME) is a leading diversified industrial company with over \$6bn in sales divided into the Electromechanical Group (EMG) and the Electronic Instruments Group (EIG). EMG produces a wide range of motor products whereas EIG is focused primarily on measurement instrumentation. The company's strategy revolves around completing bolt-on acquisitions to drive growth.

## Bath & Body Works Inc. (BBWI)

**Lorraine Hutchinson, CFA**

Research Analyst

BofAS

+1 646 855 0951

[lorraine.hutchinson@bofa.com](mailto:lorraine.hutchinson@bofa.com)

**Buy, PO \$45**

**2Q investment thesis**

We think BBWI will continue to benefit in 2025 from underlying momentum in the business, as well as product newness and innovation which should provide a pathway to



sales and margin recovery despite a tough consumer backdrop. BBWI reported a strong 4Q driven by accelerating traffic and conversion trends and positive customer response to its holiday collection. 1Q and F25 sales growth guidance of 1-3% represents a nice inflection and could prove conservative if collaborations drive incremental sales, candles return to growth or new launches gain incremental traction. Our PO of \$45 values BBWI at 8x our F26 estimated EV/EBITDA. This multiple reflects its history of, and our outlook for, consistent growth. We expect BBWI to withstand a consumer slowdown better than peers due to its affordably luxury stance and replenishment model. We think if BBWI follows its strong 4Q performance with positive sales growth at the high end of guidance (+1-3%) in 1Q, the stock would re-rate.

#### Table 4: Bath & Body Works Inc. key stock data

We highlight BBWI as a 2Q25 top pick

Industry	Consumer Distribution & Retail
Market Cap (mn)	\$9,789.78
Price	\$30.32
P/E (2026)	8.6x
% of sell-side rated Buy	75%
Short interest % of float	3.5%

Source: BofA Global Research estimates, Bloomberg

BofA GLOBAL RESEARCH

#### Catalysts:

**Strong innovation pipeline in 2025:** BBWI is set to launch a similar level of innovation in 2025 vs 2024, with several new collaborations launching throughout the year.

Collaborations such as the Disney Princess collection in February have led to strong traffic and conversion rates and been a key driver of BBWI's return to positive sales growth. Growing adjacent categories (Men's, Hair, Lip, Laundry) remains another key focus. New categories add almost 80% of total addressable market (TAM) to BBWI's existing categories. In 2025, BBWI will use tailored marketing activations (sporting events, Tik Tok) to engage with different customer segments such as men and younger consumer. Management also continues to emphasize its strong value proposition, a key driver of its performance despite a broader consumer slowdown.

**Strong cash flow and potential additional share buybacks:** BBWI's free cash flow remains strong, and we see opportunity for \$300-350mn of incremental share buybacks beyond its \$300mm guidance. We model F25 FCF of \$820mm. BBWI will pay \$170mn for the dividend and has guided to \$300mn of buybacks leaving \$350mn of cash that can be deployed for further share or debt repurchases. We view shareholder returns as a key driver of BBWI's multiple.

**Competitive advantage from 80% US production:** High domestic exposure gives BBWI a competitive advantage relative to other retailers that are more exposed to tariffs. BBWI's Ohio Beauty Park manufacturing center accounts for 80% of its production. The company sources 10% of its product from China and 7% from Canada and Mexico (3.5% each). Tariffs on Canada/Mexico are not factored into BBWI's guidance, but the company is actively working on strategies to reduce exposure to these regions, including working with vendors to lower costs, moving manufacturing of select items to Beauty Park and taking price where possible.

**1Q Earnings results (estimated late May):** BBWI guided to 1-3% sales growth for 1Q. At our recent conference in Miami, management was confident that QTD momentum will drive sales at the high end of the 1-3% and reaffirmed all aspects of its guidance. We model GM -50bp GM in 1Q as BBWI will be lapping lower international mix from last year which carries a lower margin than domestic. Modest GM headwinds are expected to continue throughout the year (we model 14bp for F25) based on some headwind to merch margins throughout the year as new products (these have lower margins initially)



and collaboration products (BBWI must pay license fees) flow through. Partially offsetting this will be a continued benefit from last year's cost savings initiatives.

#### BofA Global Research Reports

Title: Subtitle	Primary Author	Date Published
<a href="#">Bath &amp; Body Works Inc: Conference Takeaways: management is confident in 2025 sales drivers</a>	Lorraine Hutchinson, CFA	12 March 2025
<a href="#">Bath &amp; Body Works Inc: Return to sales growth should drive multiple</a>	Lorraine Hutchinson, CFA	28 February 2025
<a href="#">Bath &amp; Body Works Inc: Sales and margin show continued momentum</a>	Lorraine Hutchinson, CFA	27 February 2025
<a href="#">Bath &amp; Body Works Inc: BBWI: You asked...is this a value trap? We think not</a>	Lorraine Hutchinson, CFA	22 January 2025

**Upside risks:** Upside risk to our price objective is if the company drives strong sales growth, leading to margin expansion and increased FCF.

**Downside risks:** Downside risk to our PO is if BBWI comps decelerate, further investments are needed or margins deteriorate.

**Company Description:** Bath & Body Works International is a retailer of personal care products. It specializes in candles, soaps, and lotions. The company distributes its products through retail stores, websites and partner locations. Most of its operations are in the US, with growing Canadian and international businesses.

## Eli Lilly (LLY)

### Tim Anderson

Research Analyst

BofAS

+1 646 743-3458

[tim.m.anderson@bofa.com](mailto:tim.m.anderson@bofa.com)

### Buy, PO \$1,000

#### 2Q investment thesis

We maintain our Buy rating on LLY, with potential for outsized growth across the next 10y. The biggest driver of this is the GLP-1 obesity category. LLY is one of two leading companies that are likely to own the vast majority of the share in the category well into the future because of various 'moats' that should protect their incumbency. Category sales - when also considering diabetes, and patients that have both obesity+diabetes - could top \$150B or more on our estimates in the mid 2030s. Apart from obesity, the rest of LLY's business is simultaneously in good shape across disease areas such as oncology, immunology, and Alzheimer's disease.

Pharma is historically defensive – is that still true today, and is LLY? Because the demand for drugs tends to be inelastic, the pharmaceutical sector is commonly viewed as defensive. As such, in recent weeks, there have been inflows into the sector – especially a small handful of large cap names where the underlying stories are deemed less controversial (e.g. JNJ, ABBV, GILD, AMGN). But is the sector still defensive today? And equally, is LLY? Ongoing disruption from the Trump administration to important





healthcare agencies like HHS, CDC, and FDA creates an element of risk and uncertainty that wasn't there before – and add to that proposed tariffs that might be imposed on the sector. These make the sector less predictable, and less “safe,” in our view. Regarding LLY specifically, we note that it faces risks in the form of numerous binary events that lie ahead in 2025 (see next section). By definition, this leaves open the possibility that these events play out unfavorably or surprise to the downside – but when we consider the likelihood of each event and aggregate them together, we still end up with a positive view on the stock.

#### Table 5: Eli Lilly key stock data

We highlight LLY as a 2Q25 top pick

Industry	Pharmaceuticals
Market Cap (mn)	\$826,225.90
Price	\$825.91
P/E (2025)	35.4x
% of sell-side rated Buy	80%
Short interest % of float	0.75%

Source: BofA Global Research estimates, Bloomberg

BofA GLOBAL RESEARCH

#### Catalysts:

A very busy year ahead for LLY: LLY arguably has more catalysts and news flow ahead of it in 2025 compared to any other large cap biopharma name we cover. Further, these are in the ultra-high profile category of obesity/diabetes which is still a dominant theme, as the industry is still only in the “early innings” of rolling out therapies in this market which is likely to be largest TAM that the drug industry has ever commercialized products in. Among the more meaningful events are:

Orforglipron (oral GLP1) ph3 trial results – 7 of them. LLY's most advanced oral incretin for obesity and T2D (with plans now to also study in hypertension). Demonstrated efficacy that was roughly in line with injectable semaglutide (Novo's Wegovy) in a Ph 2 obesity trial and Ph 2 T2D trial. A very important product with many read-outs in 2025. The first readout is from ACHIEVE-1 (in diabetics), expected in 2Q25.

Retatrutide ph3 trial results before year-end – on to the “next-gen” product already? It seems LLY has just begun to roll out Zepbound/tirzepatide, its class-leading injectable GLP1. Yet the company is already far along in advancing its “next-gen” injectable product for obesity and diabetes, retatrutide (aka “triple G”). A Ph 2 trial in obese non-T2D demonstrated category-leading weight loss, which seems to meet the “step-change” vs Zepbound that LLY was aiming for (up to -24.2% weight loss at 48 weeks, vs up to ~20.5% with tirzepatide at the same timepoint in SURMOUNT-1). Ph 2 efficacy data in T2D were also strong with blood sugar control that looks almost as good as tirzepatide but with greater weight loss (up to -2.16% HbA1c lowering and up to -16.9% weight loss at 36 weeks). However, on the safety side, there were some unique toxicities to monitor going forward. Sizable Ph 3 programs in obesity (TRIUMPH) and T2D (TRANSCEND-T2D) are underway, with the first readout expected in late 2025 (TRIUMPH-4 in obesity and osteoarthritis of the knee).

SURPASS-CVOT. An important trial LLY is conducting that assesses CV safety – a head-to-head trial of tirzepatide against Trulicity. It is unusual, in our view, that LLY would choose to run such a trial against its own market-leading brand. Tirzepatide will likely beat Trulicity, but we view this potentially as an unnecessary roll of the dice, versus studying the drug against a weaker competitor GLP1. Readout expected around mid-2025.

IRA-related “negotiated” price on NOVO's Ozempic/Wegovy. IRA “maximum fair price” disclosure for drugs on the 2027 list include NOVO's Ozempic/Wegovy/Rybelsus/semaglutide by Nov 30, 2025. This will put indirect pressure





on other brands in the category, if negotiated prices in fact end up being lower than today's net price.

Competitor data sets. There are many of these to monitor. Among the more important in 2025 are (chronologically): 1) update from PFE's danuglipron QD dose optimization in 1Q25, 2) update on ABBV's amylin (GUBamy) likely in April 2025, 3) full data for NOVO's CagriSema REDEFINE-1 and 2 at ADA in June, 4) full data for AMGN's MariTide Ph 2 in obesity (T2D and non-T2D) at ADA, 5) NOVO's CagriSema REDEFINE-4 Ph 3 H2H vs LLY's tirzepatide readout in obesity in 2H25 (PCD Aug 2025), and 6) NOVO's semaglutide in Alzheimer's disease in 2H25 (Ph 3 EVOKE and EVOKE-PLUS).

#### BofA Global Research Reports

Title: Subtitle	Primary Author	Date Published
<a href="#">Health Care: GLP-1 compounding under 503A – Expert call takeaways - TRANSCRIPT INSIDE</a>	Allen Lutz, CFA	31 March 2025
<a href="#">Johnson &amp; Johnson: Thesis review, ahead of our Wednesday webcast with management</a>	Tim Anderson	25 March 2025
<a href="#">US Biopharmaceuticals: Catalysts in Context (March, 2025)</a>	Tim Anderson	06 March 2025
<a href="#">US Biopharmaceuticals: "Defensive" large-cap biopharma names on the move – updating select POs</a>	Tim Anderson	05 March 2025

**Upside risks:** 1) tirzepatide faces more smaller competitive threats than we are anticipating, 2) "next-gen" obesity products like orforglipron and retatrutide do better in Phase 3 than we are anticipating, 3) obesity TAM is larger than we anticipate.

**Downside risks:** 1) a tirzepatide safety issue arises, or faces greater competitive threats than we are anticipating, 2) "next-gen" obesity products like orforglipron and retatrutide fail in Phase 3, 3) something that fundamentally changes the size of the obesity TAM.

**Company Description:** Eli Lilly (LLY) is a large diversified biopharmaceutical company that develops, manufactures, and commercializes therapies in the areas of cardiometabolic, neuroscience, oncology and immunology.

## Energy Transfer, ET

### Jean Ann Salisbury

Research Analyst

BofAS

+1 646 855-5855

[jeanann.salisbury@bofa.com](mailto:jeanann.salisbury@bofa.com)

### Buy, PO \$23

#### 2Q investment thesis

YTD, Energy Transfer has been one of the worst performers in midstream. We believe this was likely due to 1) an overdone negative AI reaction post-Deepseek (despite ET not actually having material existing EBITDA tied to AI), 2) Canada tariff uncertainty keeping their Big Sky project from having a successful open season, and 3) Putting out a high growth capex number in their 2025 guidance as investors were looking to be more defensive.



We believe at this valuation, which does not assume much value above the dividend stream, the setup is attractive for ET going into Q2.

#### Table 6: Energy Transfer key stock data

We highlight ET as a 2Q25 top pick

Industry	Energy
Market Cap (mn)	\$68,789.59
Price	\$18.59
P/E (2025)	10.9x
% of sell-side rated Buy	94%
Short interest % of float	0.89%

Source: BofA Global Research estimates, Bloomberg

BofA GLOBAL RESEARCH

#### Catalysts:

Mid-2025 startup of major Natural Gas Liquids (NGL) export expansion: NGL exports are at capacity from the US, and we anticipate that when this \$1.5b capex project starts online it will ramp quickly through the end of the year.

Widening Permian gas differential: As the Permian basin has run out of gas egress earlier than expected, Energy Transfer should get unexpected upside (historically has been several hundred million in EBITDA) from the widening price differential between the Permian and the Gulf Coast. We believe this is upside vs guidance/consensus that will start to be baked in this quarter.

Rotation back into more “growthy” names vs defensive: YTD there has been a preference for defense which has caused names with less capex and growth to outperform. We believe there is now very little “AI” baked into the valuation and that as the short-cycle capex starts to appear over the next 1-2 quarters, investors will likely rotate back into this name.

#### BofA Global Research Reports

Title: Subtitle	Primary Author	Date Published
<a href="#">Integrateds, Refining, and Midstream: Permian NGL growth &amp; intg'd gas-power solutions key themes for 4Q earnings</a>	Jean Ann Salisbury	18 February 2025
<a href="#">Energy Transfer LP: \$5bn '25 growth capex high but mostly generates short cycle NGL EBITDA growth</a>	Jean Ann Salisbury	11 February 2025

**Upside risks:** Upside risks to our PO are: Faster growth of oil, gas, and Natural Gas liquids volumes due to 1) higher oil price or 2) rising gas production in the Permian.

**Downside risks:** Lower oil price due to OPEC barrels potentially coming back, potential rate pressure due to pipeline overbuild.

**Company Description:** Energy Transfer is a diversified midstream company with operations in oil, gas, and natural gas liquids pipelines as well as processing plants and exports.

## Goldman Sachs (GS)

**Ebrahim H. Poonawala**

Research Analyst



BofAS  
+1 646 743 0490  
[ebrahim.poonawala@bofa.com](mailto:ebrahim.poonawala@bofa.com)

## Buy, PO \$700

### 2Q investment thesis

We see the potential for a strong trading environment to persist given Trump policy actions and rapid changes to outlook for global monetary policy, regulatory relief on capital and on day-to-day running of the business (June stress test results watched), steady execution on improving firmwide profitability and growing the contribution from the asset and wealth management business all as potential catalysts to drive investor interest into the name. While M&A/IPO activity has had a slow start to the year, we believe any visibility on the policy front could jumpstart deal-making activity over the coming months.

Our \$700 PO is based on 50% P/E (equal weight FY25/26e) and 50% P/TBV (equal weight FY25/26e). We assign multiples of 14.8x/13.8x to FY25/26 EPS, 2.3x/2.2x to FY25/26 TBV, above the bank's 5-year pre pandemic median of 10.1x/1.2x given potential for a positive EPS revision cycle and upside to our EPS/ROE forecast.

### Table 7: Goldman Sachs key stock data

We highlight GS as our 2Q25 top pick

Industry	Financials
Market Cap (mn)	\$250,683.07
Price	\$546.29
P/E (2025)	12.3x
% of sell-side rated Buy	54%
Short interest % of float	1.28%

Source: BofA Global Research estimates, Bloomberg

BofA GLOBAL RESEARCH

### Catalysts:

Regulatory capital relief coming out of stress test results (2H June), SLR focus among policymakers: We expect regulatory CET1 capital requirements to decline coming out of the 2025 stress test results (late June). Recall, the minimum requirement surprisingly went up by 70bp last year despite actions taken by management to de-risk the balance sheet. Improved transparency on stress test framework, a more balanced regulatory backdrop should drive capital requirements lower, potentially push structural ROE higher vs. mgmt's mid-teens target. Minimum CET1 capital requirement at 13.7% vs. 9.5% in 2019 (pre-SCB) and 13.6% end of 2020 (first year post SCB framework was instituted).

Strong trading revenues to offer EPS/ROE defensibility: While investors tend not given a ton of credit to a trading driven EPS beat, in an environment where the economy risks hitting stall speed, the heightened volatility is likely to serve as more of a tailwind to trading revenues vs. headwind.

M&A and IPO activity delayed but not off the table: Strong banking franchise to capture pickup in M&A and IPO activity. Recent M&A announcements (such as Alphabet/Wiz) suggests window for larger deals under new DOJ/FTC leadership opening. A Capital One/Discover merger approval would be an important data point in informing investor views on M&A activity.

Asset and Wealth Management tailwind: Improving execution towards growing "durable" revenues and boosting franchise profitability in the Asset and Wealth Management business (~25% to bottom line). Achieved medium-term mid-twenties pre-tax margin target and now focused on driving returns towards mid-teens. Pre-tax margin more than doubled YoY in 2024 to 28% (24% excluding the impact from the sale of investments held on the balance sheet) from 10%.



Credit defensibility in a worsening consumer backdrop: Shifted away from consumer strategy (-19% ROE in 2024) and maintains limited exposure vs. money center and regional bank peers into a weakening consumer, small business backdrop due to DOGE led austerity, tariff headwinds.

### BofA Global Research Reports

Title: Subtitle	Primary Author	Date Published
<a href="#">US Banks: BofA 2025 Financial Services Conference takeaways: 3Rs firmly intact</a>	Ebrahim H. Poonawala	18 February 2025
<a href="#">Goldman Sachs: A lot to play for</a>	Ebrahim H. Poonawala	15 January 2025
<a href="#">Goldman Sachs: 2025 Year Ahead: Proving that it's worth it</a>	Ebrahim H. Poonawala	07 January 2025

**Upside risks:** Stronger capital markets activity, better than anticipated capital relief

**Downside risks:** Weaker economy/capital markets, macro or geo-political issues, competition, structural pressures, tougher global regulation, and litigation

**Company Description:** The Goldman Sachs Group, Inc. (GS) is a global investment banking, securities, and investment management firm with leading positions in M&A, equity underwriting, and equity trading. The firm also generates significant revenues from its investing, lending, and FICC businesses, and is focused on growing its investment management business.

## Ralph Lauren (RL)

### Christopher Nardone

Research Analyst

BofAS

+1 646 743 2016

[christopher.nardone@bofa.com](mailto:christopher.nardone@bofa.com)

### Buy, PO \$318

#### 2Q Investment thesis

We think RL offers an attractive risk/reward at 9x EV/EBITDA due to the combination of strong global brand heat, structural margin drivers, a strong balance sheet, and a diversified supply chain. RL reported strong holiday results driven by better sales and a pullback in promotions in each region (US, Europe, Asia). We expect improving brand heat globally will continue to drive above average sales growth trends (vs peers) and think the company has levers to drive continued margin expansion. Our PO of \$318 is based on 13.5x FY27E EV/EBITDA, higher than peers due to its long-term brand value, strong balance sheet, and stronger margins.

#### Table 8:Ralph Lauren key stock data

We highlight RL as a 2Q25 top pick

Industry	Consumer Apparel
Market Cap (mn)	\$18,276.60
Price	\$220.74
P/E (2026)	15.7x
% of sell-side rated Buy	65%
Short interest % of float	6.3%

**Source:** BofA Global Research estimates, Bloomberg

BofA GLOBAL RESEARCH



**Catalysts:**

4Q25 earnings results (estimated mid-May): RL's next earnings release in mid-May is an important catalyst since management will provide initial guidance for F26. We expect the core customer for RL will remain resilient and feel confident that the company can deliver on its 4Q sales guidance of 6-7% ccy and op margin guidance of +120-140bp ccy. We expect Asia and Europe will continue to drive total company sales growth and think results in the US will remain solid. Our F26E earnings forecast of \$13.75 implies 14% earnings growth.

International momentum continues: Beyond 4Q, we expect RL to deliver MSD total sales growth (ccy) and think international will continue to drive the business. In Asia (24% of sales), RL continues to buck the macro volatility in China (3Q sales +20%). We see more opportunity for further AUR gains in Asia. In Europe (30% of sales), RL is seeing broad-based strength across markets, including a return to growth in the UK following several quarters of volatility.

North America wholesale stabilizing: We were pleased to see a return to N.A. wholesale growth in 3Q25 and expect flattish sales in this segment for the foreseeable future. This is a major inflection point for a high-margin business following several quarters of declining sales. While there are still secular challenges in the channel, we think RL will likely continue to emerge as a share gainer. We expect increased penetration in luxury wholesale doors and focus on product expansion in women's apparel and handbags. The improved brand heat and investments in DTC are now carrying over into wholesale.

More opportunities for gross margin expansion: We expect structural margin drivers such as mix (product, international, channel) and a pullback in promotions will drive steady AUR gains beyond 4Q and into F26. We were encouraged by the significant pullback in promos globally last quarter and view this as a strong sign that brand heat is gaining momentum. Lower cotton costs are expected to drive around 80bp of GM expansion in F26 and should help offset headwinds from non-cotton input costs, labor, overhead, and tariffs.

Tariffs challenging for sector, but better positioned than most: Tariffs remain a key concern for the sector, but we think RL's diversified sourcing footprint and ability to take price puts them in a better position vs most apparel and footwear peers. RL's sourcing exposure to China is low at a MSD % of total sourcing.

**BofA Global Research Reports**

<b>Title: Subtitle</b>	<b>Primary Author</b>	<b>Date Published</b>
<a href="#">Ralph Lauren: Conference takeaways: Time for brand elevation strategy to shine</a>	Christopher Nardone	13 March 2025
<a href="#">Ralph Lauren: Accelerating sales trends and continued margin opportunities keeps us bullish</a>	Christopher Nardone	06 February 2025
<a href="#">Ralph Lauren: CEO/CFO meeting takeaways: Elevation strategy has momentum</a>	Christopher Nardone	09 December 2024

**Upside risks:** Include a faster-than-expected sales turnaround, higher-than-expected benefits from ongoing cost savings initiatives, and significant improvements in the overall global apparel retail environment.

**Downside risks:** Downside risks are worse-than-expected trends at wholesale, incremental US department store closures, higher-than-expected reinvestment spending, and deterioration in the global macro environment.

**Company Description:** Ralph Lauren designs and distributes apparel, accessories, housewares and fragrances through wholesale department stores, specialty stores, retail stores and online.



# RenaissanceRe (RNR)

## Joshua Shanker

Research Analyst

BofAS

+1 347 821 9017

[joshua.shanker@bofa.com](mailto:joshua.shanker@bofa.com)

## Buy, PO \$426

### 2Q investment thesis

Shares of RenRe have derated to near-historic multiple lows on an absolute basis and absolute lows on a relative to industry peer group basis. Ironically, this is occurring at a time when its underlying earnings power (investment income plus attritional underwriting income) are at 20-year highs. Further, the risk to the balance sheet poised by catastrophe loss events seems less significant to the company than it did 20 years ago when it last was achieving these levels of return on capital. We expect 1Q25 earnings results to be a positive catalyst as investors digest that, in a quarter with significant LA wildfire losses, the company nearly broke even (with what we forecast to be modest book value per share growth). Our \$426 12-month price objective is based on 20% discount to the P&C underwriter group's 10.8x 2026 consensus P/E multiple applied to our 2027 EPS forecast of \$49.40. For most of its history, RenRe has traded close to in-line with the peer group (or even at a premium) and now trades at a 40% discount.

### Table 9: RenaissanceRe key stock data

We highlight RNR as our 2Q25 top pick

Industry	Insurance
Market Cap (mn)	\$11,717.90
Price	\$240.00
P/E (2025)	10.4x
% of sell-side rated Buy	45%
Short interest % of float	3.01%

Source: BofA Global Research estimates, Bloomberg

BofA GLOBAL RESEARCH

### Catalysts:

We expect 1Q25 results to corroborate strong operating fundamentals: 1Q25 is a difficult quarter for the insurance industry. The LA wildfires seem to present a \$50bn loss event to the industry, and the American Airlines plane crash represents the worst U.S. aviation disaster in 23 years. With this backdrop, RenRe will likely take losses that will essentially wipe out 1Q25 EPS. However, in past years, such significant losses would create a large loss per share for the company. However, net investment income and attritional underwriting income have grown so strongly that these major headwinds have been mitigated to a quarter we expect to be (just below) breakeven. Further, declining interest rates should likely deliver mark-to-market growth in the bond portfolio such that book value actually grows in 1Q25 despite large catastrophe headwinds.

Pricing trends to remain attractive: Bears have clung to the idea that property-cat pricing being down 5-10% to start 2025 (on January 1) off all-time highs in 2024 was a bad outcome for reinsurers. We expect this to be the same news out of 4/1 renewals (Japan and South Korea) and 6/1 renewals (Florida). We do not expect incremental softening following the five-month stretch of Hurricane Helene-Hurricane Milton-LA wildfires. With 2025 shaping up to be as difficult a year for catastrophes as any as the



insurance industry has faced in the past, the desire of reinsurers to give up on pricing appears to be low. In our view, the property-cat markets are always just one event away from a disaster that can create enough fear (and destroy capital) that brings pricing to new all-time highs.

Significant capital return expected: RenRe has bought back over 10% of its sharecount six times in the past 17 years and we expect 2025 to be the seventh. In late 2024, its board of directors increased its quarterly buyback authorization to \$750mn, noting that the prior authorization of \$500mn would not be enough to allow the company to be 10% of daily volume in its own shares. The LA wildfires caused the buyback to slow as cashflow has been redirected toward urgent claims payments, but we expect the pace of buybacks to ramp in 2Q25 and 4Q25. (Summertime buybacks tend to be less aggressive awaiting the outcome of the hurricane season.)

#### BofA Global Research Reports

Title: Subtitle	Primary Author	Date Published
<a href="#">RenaissanceRe: Reserve adequacy doubts appear unfounded; repurchases to surge</a>	Joshua Shanker	11 November 2024
<a href="#">U.S. Insurance: How to play defense in a volatile market: Arch Capital, reinsurers and "total return"</a>	Joshua Shanker	14 March 2025
<a href="#">RenaissanceRe: Rain or shine, an uncommon business at an uncommonly discounted valuation</a>	Joshua Shanker	26 March 2025

**Upside risks:** Upside risks to our PO are: 1) Quicker book value compounding in the absence of regularly expected catastrophe activity, and 2) A sudden return to parity-with-peer valuation multiples that haven't been seen in three-plus years.

**Downside risks:** 1) The company is materially exposed to catastrophe loss events, which can cause a high degree of volatility in both directions, but usually begins with selling the stock in the face of disaster, 2) A significant decline in interest rates (like 2% U.S. Treasury yields), which typically invites non-traditional capital to compete against reinsurers at a much lower required return, and 3) The emergence of adverse development on prior-year loss reserves.

**Company Description:** RenaissanceRe, formed out of the massive property-catastrophe losses in 1992's Hurricane Andrew, is widely considered the property-catastrophe reinsurance "specialist." During sliding prices for property-cat risk from 2012-2018, RenRe took it as an opportunity to broaden its underwriting footprint into more liability-sensitive risks. These investments have yet to prove their value, but the risk profile of the company is now fairly diversified.

## The Trade Desk, Inc. (TTD)

### Jessica Reif Ehrlich

Research Analyst

BofAS

+1 646 855 2921

[jessica.reif@bofa.com](mailto:jessica.reif@bofa.com)





## Buy, PO \$130

### 2Q investment thesis

The Trade Desk (TTD) is a leading, independent demand-side platform (DSP) that enables brands and advertisers to buy ads programmatically across media. TTD's best-in-class DSP as well as its unique positioning within digital advertising has led to substantial growth. However, in February, TTD reported disappointing 4Q results which missed our revenue and adj EBITDA forecasts and guidance (first miss in 33 quarters as a public company). The stock is down over 50% since reporting earnings. Key concerns in the business include the threat of increasing competition from Amazon, a slower than anticipated uptake of its Kokai platform and overarching macroeconomic concerns as it relates to the cyclical advertising business.

We see the opportunity as unchanged and believe TTD will be able to weather these concerns and outperform, driven by secular drivers including: 1) continued shift of traditional media advertising dollars to digital channels, 2) sustained momentum in CTV supported by various partnerships that remain in early days (e.g. Netflix, Disney with OpenPath, Roku, Fox, NBC, etc.), 3) the unlock of retail media/data which remains in early stages, 4) ramping adoption of OpenPath (helped, in part, by the transition to Kokai) and 5) growth in audio (partially driven by new SPOT partnership). Additionally, TTD's position as an independent proponent of the open internet ecosystem should continue to drive strong advertiser and publisher partnerships.

We believe TTD's competitive positioning in high growth areas of digital advertising with large TAMs, particularly CTV and retail media, as well as growth in Audio and International, should support the company's multiple. We are Buy rated with a \$130 PO (~45x CY26E EBITDA).

#### Table 10: The Trade Desk key stock data

We highlight TTD as our 2Q25 top pick

Industry	Advertising & Marketing Services
Market Cap (mn)	\$54,961.33
Price	\$54.72
P/E (2025)	23.4x
% of sell-side rated Buy	73%
Short interest % of float	5.21%

Source: BofA Global Research estimates, Bloomberg

BofA GLOBAL RESEARCH

### Catalysts:

Earnings results (May 8<sup>th</sup> - estimated): We anticipate TTD's 1Q25 results will be at least in line with guidance for revenue and adj. EBITDA. This will be a crucial quarter for TTD, as it is important for the company to prove they can return to their previous beat and raise cadence. Additionally, commentary around competition, the macro environment and updates on the Kokai transition are likely to drive sentiment in stock.

Additional partnerships and uptake of TTD's tool for advertisers and publishers: TTD has struck various partnerships that remain in early days (e.g. Netflix, Spotify, Disney with OpenPath, Roku, Fox, NBC etc.) and should sustain growth for the foreseeable future. To the extent more participants in the advertising ecosystem partner with TTD and use the company's tools, it should result in share gains over time. We anticipate TTD will continue to announce partnerships, particularly for newer products such as OpenPath and Ventura.

Google ad tech DOJ case: Google is currently awaiting a judge ruling in their ad tech antitrust trial brought by the DOJ. If Google is forced to divest a part of their ad tech business, it could be a positive for TTD to the extent it weakens a direct competitor and creates a fairer and more open digital advertising ecosystem. It is worth noting that a ruling in favor of Google, would likely maintain the current status quo, and should not have a negative impact on TTD.



**BofA Global Research Reports**

<b>Title: Subtitle</b>	<b>Primary Author</b>	<b>Date Published</b>
<a href="#">The Trade Desk, Inc.: Don't overthink a missed free throw</a>	Jessica Reif Ehrlich	03 March 2025
<a href="#">The Trade Desk, Inc.: Resetting the Trade</a>	Jessica Reif Ehrlich	13 February 2025
<a href="#">The Trade Desk, Inc.: Trading higher</a>	Jessica Reif Ehrlich	09 December 2024

**Upside risks:** Upside risks to our price objective are faster-than-expected revenue growth, acceleration in the shift from traditional linear TV to CTV and other digital advertising channels, increased market share, increased operating leverage and a quicker ramp with new partnerships, as well as announcements of new media partnerships.

**Downside risks:** Downside risks to our PO are downward pressure on TTD's take rate, increasing competition (particularly from Amazon), slower than expected adoption of Kokai, macroeconomic headwinds in the advertising business and potential regulation related to data privacy and collection impairing the company's ability to do business.

**Company Description:** The Trade Desk offers a self-service, cloud-based ad-buying platform that empowers clients to plan, manage, optimize and measure data-driven digital advertising campaigns. TTD's platform allows clients to execute campaigns across ad formats and channels, including video (which includes CTV), display, audio, digital-out-of-home, native and social, on a multitude of devices, such as computers, mobile devices, TVs and streaming devices.

## Hims and Hers Health (HIMS)

### Allen Lutz, CFA

Research Analyst

BofAS

+1 646 855 4380

[allen.lutz@bofa.com](mailto:allen.lutz@bofa.com)

### Underperform, \$22 PO

#### 2Q Investment Thesis

HIMS is a direct-to-consumer pharmacy that allows patients to buy prescription drugs for conditions like erectile dysfunction, hair loss, and weight loss without having to physically see a physician. The company has grown quickly to ~\$2.3Bn of annualized sales, but its fastest growing business, compounded semaglutide for weight loss, will be exiting the model soon or the company will face patent infringement or broader litigation from Novo Nordisk, the FDA, or both.

HIMS' recent revenue acceleration is driven by a loophole in federal drug regulations (FD&C Act and FDA guidance) that allows compound pharmacies to sell drugs while the branded versions are on shortage. However, this drug (semaglutide) is no longer in shortage, meaning HIMS will need to exit this business by May 22nd. While the company intends to continue to and sell "personalized" dosages of compounded GLP-1s thereafter, our conversations with patent attorneys suggest that would lend to litigation risk.

HIMS' semaglutide business went from \$0 in May 2024 to exiting February 2025 at a ~\$1Bn annualized run-rate, making up ~40% of total sales. At the same time, growth in



HIMS' core business (everything excluding GLP-1s) has slowed from 47-50% in 3Q24 to exiting February at ~30%. The rapid growth in GLP-1s combined with the meaningful deceleration in the broader business puts guidance and street estimates at risk. HIMS stock has outperformed to date by beating and raising relative to expectations, but we believe this set-up is unlikely to continue given the headwinds discussed above. Our \$22 PO is based on 17x 2025E EV/EBITDA.

#### Table 11: Hims & Hers Health Inc. key stock data

We highlight HIMS as our 2Q25 top pick

Industry	Health Care
Market Cap (mn)	\$7,084.93
Price	\$29.55
P/E (2026)	45.5x
% of sell-side rated Sell	12%
Short interest % of float	31.17%

Source: BofA Global Research estimates, Bloomberg

BofA GLOBAL RESEARCH

#### Catalysts:

Litigation from big pharma after 503A deadline (April 22<sup>nd</sup>) and risk of treble damages: HIMS was able to sell compounded semaglutide GLP-1s under the statutory guidelines during a drug shortage. However, FDA considered the semaglutide drug shortage as resolved last month. FDA guidelines indicate 503A pharmacies and 503B pharmacies need to halt compounding and distribution of semaglutide by April 22<sup>nd</sup> and May 22<sup>nd</sup>, respectively. HIMS intends to continue and sell “personalized” compounded semaglutide under the “compound exemption” within the 503A FDA guidelines. However, patent attorneys and industry experts we spoke to disagree with this assessment of the FDA guidance. For example, allowing compound pharmacies to sell “inordinate amounts” of personalized doses of drugs for which they have no patent would render broader patent law as useless. We expect Novo Nordisk, the manufacturer of branded semaglutide to sue 503A pharmacies like HIMS that sell compounded semaglutide at scale after April 22<sup>nd</sup>. As such, we see risks of treble damages for HIMS under patent infringement lawsuits.

Slowing core growth: While we expect HIMS to significantly beat 1Q'25 Street estimates driven by accelerating GLP-1 contributions, we see core growth slowing ([see our February data note](#)), putting FY25 guidance at risk. FY25 guidance contemplates 43-52% y/y growth ex-weight loss, an acceleration in core while our analysis of Bloomberg credit and debit card data suggest that the core is decelerating (1Q core growth could be 30% vs. 39% in 4Q and 47-50% in 3Q). As the market begins to appreciate the limited duration of the compounded GLP-1 opportunity, we expect the slowdown in core growth to result in downward revisions to estimates beyond 1H'25.

#### BofA Global Research Reports

Title: Subtitle	Primary Author	Date Published
<a href="#">Health Care: GLP-1 compounding under 503A – Expert call takeaways - TRANSCRIPT INSIDE</a>	Allen Lutz, CFA	31 March 2025
<a href="#">Health Care: Takeaways from our latest expert call on GLP-1 compounding: TRANSCRIPT INSIDE</a>	Allen Lutz, CFA	19 March 2025
<a href="#">Hims &amp; Hers: February data: GLP-1s are driving significant upside in 1Q</a>	Allen Lutz, CFA	18 March 2025

**Upside risks:** Upside risks to our PO are: 1) Acceleration in core growth supported by cross selling, new product introductions, and/or an improvement in marketing efficiency  
2) Extended duration of the compounded GLP-1 opportunity at scale beyond 1H'25.



**Downside risks:** Downside risks are lack of differentiation vs. more traditional pharmacy providers, a limited number of disease categories serviced, the need to continue to spend on both R&D and sales & marketing to remain competitive, and a slower return of overall market script growth post-COVID.

**Company Description:** Hims and Hers Health is a cash-pay online pharmacy platform that offers online consultations and prescriptions for various health conditions, with drugs delivered directly to consumers. The company began selling sexual health products such as generic Viagra, and has expanded to categories such as hair loss, dermatology, mental health, and weight loss. HIMS generates significant margins relative to retail pharmacy and other traditional online pharmacy peers by selling different form factors and combinations of generic drugs at premium prices. HIMS value proposition resides in a low-friction, completely online experience for consumers under a subscription model that circumvents the traditional healthcare model. The company has grown revenue from <\$150MM in 2020 to \$1.4Bn+ in 2024 with the subscriber base growing from <300k to 2MM+ during the same time frame.

## Price objective basis & risk

### Agnico Eagle Mines (AEM)

Our \$119 per share price objective is based on Agnico Eagle trading at 2.5x times our estimated NAV (current net debt position plus a mining asset DCF utilizing a 5% WACC). Historically, North American gold producers have traded between 1 and 2 times NAV, with 1.75-2.0 times being accorded to the organically growth-oriented gold producers such as AEM.

Risks of this price objective not being attained are commodity price weakness, the inability to secure financing for expansion or development projects, unforeseen operating problems, and political risk in the countries the company operates in. Upside risks are commodity price strength, better-than-forecast operating performance and favorable changes in the political environment in the regions where it operates.

### AMETEK Inc (AME)

We base our \$225 price objective on a 20x EV/EBITDA multiple of our 2026 estimates. Our target multiple is a premium to the 19x peer average on 2025E, reflecting above-peer margins and track record of capital deployment.

Downside risks to our price objective are: 1) weaker industrial production trends, 2) slower pace of acquisitions, and 3) cyclical risks on shorter cycle component businesses. Upside risks are: 1) secular growth in automation and aerospace end markets, 2) accretive acquisitions, and 3) share gains for differentiated products.

### Bath & Body Works Inc (BBWI)

Our PO of \$45 values BBWI at 8x our F26 estimated EV/EBITDA. We expect BBWI to withstand a consumer slowdown better than peers due to its affordably luxury stance and replenishment model. This multiple reflects its history of, and our outlook for, consistent growth. It is below consistent compounder valuations and peer multiples to reflect higher leverage and risks that pandemic-era sales will not hold.

Upside risk to our price objective is if the company is able to continue to drive strong sales growth.

Downside risk to our PO is if BBWI comps decelerate further than our estimates call for.



**Eli Lilly (LLY)**

Our \$1,000 price objective is based on a target P/E multiple of 43x applied to our "underlying" 2025E EPS estimate. This is a large premium to the peer average, due to its outsized growth potential versus peers.

Downside risks: 1) a tirzepatide safety issue arises, or faces greater competitive threats than we are anticipating, 2) "next-gen" obesity products like orforglipron and retatrutide fail in Phase 3, 3) something that fundamentally changes the size of the obesity TAM.

**Energy Transfer LP (ET)**

Our PO of \$23 is derived from our discounted cash flow valuation, which implies a 8.3x 2026E EV/EBITDA multiple. We forecast a ten year outlook, which we believe is the limit of market recognition, and then forecast terminal growth of 1% while using a 7.0% WACC.

Downside risks are: potential shutdown of Dakota Access pipeline for extended period as per court ruling, higher leverage, dilutive M&A transaction and lower sustained commodity prices. The tax treatment of ET depends on its status as a partnership for federal income tax purposes: should ET become subject to taxes, its performance could be materially affected. From a macro perspective, financial risks are rising interest rates and a stricter regulatory environment which would increase operating and maintenance expenses.

**Goldman Sachs (GS)**

Our \$700 PO is based on 50% P/E (equal weight FY25/26e) and 50% P/TBV (equal weight FY25/26e). We assign multiples of 14.8x/13.8x to FY25/26 EPS, 2.3x/2.2x to FY25/26 TBV, above the bank's 5-year pre pandemic median of 10.1x/1.2x given potential for a positive EPS revision cycle and upside to our EPS/ROE forecast.

Downside risks to our PO: weaker economy/capital markets, macro or geo-political issues, competition, structural pressures, tougher global regulation, and litigation. Upside risks: stronger capital markets activity.

**Hims & Hers (HIMS)**

Our \$22.00 price objective is based on c.17x CY25E EBITDA implying a more mature multiple of 14-16x in outer years. We use a range of health IT companies, both newer digital health as well as more traditional software for comparison, comparing relative growth and relative margin rates, with the digital health side being more representative. Given relative growth rates, spend levels, and margin characteristics, our target multiple is in-line with some of the other digital health companies that are profitable.

Upside risks are increased demand from consumer-oriented disease categories, faster growth from targeted marketing spend (leading to stronger LTV/CAC), rapid adoption and longer duration of GLP-1 sales, and potential upside from moving into new disease categories. Downside risks are lack of differentiation vs. more traditional pharmacy providers, a limited number of disease categories serviced, the need to continue to spend on both R&D and sales & marketing to remain competitive, and a slower return of overall market script growth post-COVID.

**Ralph Lauren (RL)**

Our PO of \$318 is based on 13.5x FY27E EV/EBITDA, higher than peers trading at 9x due stronger margins and sales growth. We think RL should trade at a slight premium to peers given its long-term brand value, strong balance sheet, and stronger margins.

Upside risks to our PO are a faster-than-expected sales turnaround, higher-than-expected benefits from ongoing cost savings initiatives, and significant improvements in the overall global apparel retail environment. Downside risks are worse-than-expected



trends at wholesale, incremental US department store closures, higher-than-expected reinvestment spending, and deterioration in the global macro environment.

**RenaissanceRe (RNR)**

Our \$426 PO is based on a 20% "reinsurance/offshore" discount to the 2026 large-cap peer P&C year-ahead P/E multiple (10.8x) on our 2027E EPS forecast. We view a discount as appropriate based on the historical discount and noting that reinsurance tends to be viewed as a derivative market already closer to the higher-end of its underwriting margins than its primary insurance "peers."

Downside risks are: the pressure from lower interest rates causing a decline in earnings power and potentially leading the company to miss our EPS expectations. The volatility associated with catastrophes also creates the risk of missing or exceeding our EPS outlook. Estimates for unprecedented wildfire in California are higher/lower than our estimates.

**The Trade Desk, Inc. (TTD)**

Our \$130 PO is based on approximately 45x CY26E EV/EBITDA. Our approximate 45x multiple represents a roughly 15% discount to a group of high-growth tech peers with similar revenue growth characteristics. We believe that a discount to this comp group is warranted given TTD's slightly slower projected EBITDA growth rate in CY26E.

Downside risks to our PO are downward pressure on TTD's take rate, increasing competition (particularly from Amazon), slower than expected adoption of Kokai, macroeconomic headwinds in the advertising business and potential regulation related to data privacy and collection impairing the company's ability to do business.

**Analyst Certification**

We, Anthony Cassamassino, Allen Lutz, CFA, Andrew Obin, Christopher Nardone, Ebrahim H. Poonawala, Jean Ann Salisbury, Jessica Reif Ehrlich, Joshua Shanker, Lawson Winder, CFA, Lorraine Hutchinson, CFA and Tim Anderson, hereby certify that the views each of us has expressed in this research report accurately reflect each of our respective personal views about the subject securities and issuers. We also certify that no part of our respective compensation was, is, or will be, directly or indirectly, related to the specific recommendations or view expressed in this research report.

**Special Disclosures**

BofA Securities is currently acting as Exclusive Financial Advisor to TietoEVERY Oyj in connection with its proposed sale of Tietoevry Tech Services to Agilitas Partners LLP, which was announced on March 23, 2025.

**US - Cable, Entertainment and Satellite Coverage Cluster**

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
<b>BUY</b>				
	Charter Communications	CHTR	CHTR US	Jessica Reif Ehrlich
	Fox Corporation	FOXA	FOXA US	Jessica Reif Ehrlich
	Fox Corporation	FOX	FOX US	Jessica Reif Ehrlich
	Live Nation Entertainment	LYV	LYV US	Peter Henderson
	Madison Square Garden Entertainment	MSGE	MSGE US	Peter Henderson
	Netflix, Inc.	NFLX	NFLX US	Jessica Reif Ehrlich
	Roku, Inc.	ROKU	ROKU US	Brent Navon, CFA
	Spotify Technology	SPOT	SPOT US	Jessica Reif Ehrlich
	The Trade Desk, Inc.	TTD	TTD US	Jessica Reif Ehrlich
	TKO Group Holdings	TKO	TKO US	Brent Navon, CFA
	Walt Disney Co.	DIS	DIS US	Jessica Reif Ehrlich
	Warner Bros. Discovery	WBD	WBD US	Jessica Reif Ehrlich
<b>NEUTRAL</b>				
	Comcast Corp	CMCSA	CMCSA US	Jessica Reif Ehrlich
	iHeartMedia, Inc.	IHRT	IHRT US	Jessica Reif Ehrlich
	Sphere Entertainment Co.	SPHR	SPHR US	Peter Henderson
<b>UNDERPERFORM</b>				
	Altice USA, Inc.	ATUS	ATUS US	Jessica Reif Ehrlich
	Sirius XM Holdings Inc	SIRI	SIRI US	Jessica Reif Ehrlich
	Warner Music Group Corporation	WMG	WMG US	Jessica Reif Ehrlich
<b>RSTR</b>				
	Paramount Global	PARA	PARA US	Jessica Reif Ehrlich

**US - Multi-Industrials/Engineering and Construction Coverage Cluster**

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
<b>BUY</b>				
	3M Company	MMM	MMM US	Andrew Obin
	AMETEK Inc	AME	AME US	Andrew Obin
	Applied Industrial Technologies	AIT	AIT US	Sabrina Abrams
	Atmus Filtration	ATMU	ATMU US	Andrew Obin
	Dover Corp	DOV	DOV US	Andrew Obin
	Eaton Corp PLC	ETN	ETN US	Andrew Obin
	Emerson Electric Co	EMR	EMR US	Andrew Obin
	Fastenal Company	FAST	FAST US	Sabrina Abrams
	Flowserve	FLS	FLS US	Andrew Obin
	GE Vernova	GEV	GEV US	Andrew Obin
	ITT Inc.	ITT	ITT US	Andrew Obin
	Johnson Controls International PLC	JCI	JCI US	Andrew Obin
	Parker Hannifin Corporation	PH	PH US	Andrew Obin
	PTC Inc.	PTC	PTC US	Andrew Obin
	Rush	RUSHA	RUSHA US	Andrew Obin
	Vertiv	VRT	VRT US	Andrew Obin
	Vontier	VNT	VNT US	Andrew Obin
<b>NEUTRAL</b>				
	Carrier Global Corp.	CARR	CARR US	Andrew Obin
	Fortive Corporation	FTV	FTV US	Andrew Obin
	Honeywell International Inc.	HON	HON US	Andrew Obin
	Illinois Tool Works	ITW	ITW US	Andrew Obin
	Montrose Environmental Group, Inc.	MEG	MEG US	Andrew Obin
	Pentair plc	PNR	PNR US	Andrew Obin
	Rockwell	ROK	ROK US	Andrew Obin
	Trane Technologies PLC	TT	TT US	Andrew Obin
<b>UNDERPERFORM</b>				
	Allegion	ALLE	ALLE US	Andrew Obin
	Core & Main	CNM	CNM US	Andrew Obin
	E2open	ETWO	ETWO US	Andrew Obin
	JBT Marel Corp	JBTM	JBTM US	Andrew Obin
	Keysight	KEYS	KEYS US	David Ridley-Lane, CFA





**US - Multi-Industrials/Engineering and Construction Coverage Cluster**

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
	W.W. Grainger, Inc.	GWW	GWW US	Sabrina Abrams

**US - Softline Retailing and Dept Stores Coverage Cluster**

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
<b>BUY</b>				
	Amer Sports Inc	AS	AS US	Lorraine Hutchinson, CFA
	Bath & Body Works Inc	BBWI	BBWI US	Lorraine Hutchinson, CFA
	Birkenstock	BIRK	BIRK US	Lorraine Hutchinson, CFA
	Boot Barn	BOOT	BOOT US	Christopher Nardone
	Burlington Stores	BURL	BURL US	Lorraine Hutchinson, CFA
	Crocs, Inc.	CROX	CROX US	Christopher Nardone
	European Wax Center	EW CZ	EW CZ US	Lorraine Hutchinson, CFA
	lululemon athletica Inc	LULU	LULU US	Lorraine Hutchinson, CFA
	Nike	NKE	NKE US	Lorraine Hutchinson, CFA
	Oddity Tech	ODD	ODD US	Lorraine Hutchinson, CFA
	Ollie's Bargain Outlet Holdings Inc	OLLI	OLLI US	Lorraine Hutchinson, CFA
	Ralph Lauren	RL	RL US	Christopher Nardone
	Ross Stores Inc	ROST	ROST US	Lorraine Hutchinson, CFA
	Skechers USA Inc	SKX	SKX US	Christopher Nardone
	Tapestry Inc.	TPR	TPR US	Lorraine Hutchinson, CFA
	TJX Companies	TJX	TJX US	Lorraine Hutchinson, CFA
	Torrid Holdings Inc.	CURV	CURV US	Lorraine Hutchinson, CFA
	Urban Outfitters	URBN	URBN US	Lorraine Hutchinson, CFA

**NEUTRAL**

	American Eagle	AEO	AEO US	Christopher Nardone
	Capri Holdings Ltd	CPRI	CPRI US	Lorraine Hutchinson, CFA
	Deckers Outdoor Corp	DECK	DECK US	Christopher Nardone
	Foot Locker	FL	FL US	Lorraine Hutchinson, CFA
	Gap Inc.	GAP	GAP US	Lorraine Hutchinson, CFA
	Levi Strauss & Co.	LEVI	LEVI US	Christopher Nardone
	PVH Corp	PVH	PVH US	Christopher Nardone
	Signet Jewelers	SIG	SIG US	Lorraine Hutchinson, CFA
	Ulta Beauty	ULTA	ULTA US	Lorraine Hutchinson, CFA
	Under Armour Inc	UAA	UAA US	Lorraine Hutchinson, CFA

**UNDERPERFORM**

	Carter's Inc	CRI	CRI US	Christopher Nardone
	FIGS, Inc.	FIGS	FIGS US	Lorraine Hutchinson, CFA
	Five Below	FIVE	FIVE US	Lorraine Hutchinson, CFA
	Kohl's	KSS	KSS US	Lorraine Hutchinson, CFA
	Revolve	RVLV	RVLV US	Lorraine Hutchinson, CFA
	V F Corp	VFC	VFC US	Lorraine Hutchinson, CFA
	Victoria's Secret & Co	VSCO	VSCO US	Lorraine Hutchinson, CFA

**RSTR**

	Macy's	M	M US	Lorraine Hutchinson, CFA
--	--------	---	------	--------------------------

**North America - Metals and Mining Coverage Cluster**

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
<b>BUY</b>				
	Agnico Eagle Mines	AEM	AEM US	Lawson Winder, CFA
	Alamos Gold	YAGI	AGI CN	Lawson Winder, CFA
	Alamos Gold	AGI	AGI US	Lawson Winder, CFA
	Alcoa Corporation	AA	AA US	Lawson Winder, CFA
	Cameco Corporation	YCCO	CCO CN	Lawson Winder, CFA
	Cameco Corporation	CCJ	CCJ US	Lawson Winder, CFA
	CMC	CMC	CMC US	Sathish Kasinathan
	Freeport-McMoRan	FCX	FCX US	Lawson Winder, CFA
	Hudbay Minerals	YHBM	HBM CN	Lawson Winder, CFA



## North America - Metals and Mining Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
	HudBay Minerals	HBM	HBM US	Lawson Winder, CFA
	IAMGOLD	YIMG	IMG CN	Lawson Winder, CFA
	IAMGOLD Corp.	IAG	IAG US	Lawson Winder, CFA
	Ivanhoe Mines	YIVN	IVN CN	Lawson Winder, CFA
	Ivanhoe Mines	IVPAF	IVPAF US	Lawson Winder, CFA
	Kinross Gold	KGC	KGC US	Lawson Winder, CFA
	Lundin Mining	XLPRF	LUMI SS	Lawson Winder, CFA
	Lundin Mining Corp	YLUN	LUN CN	Lawson Winder, CFA
	Lundin Mining Corp	LUNMF	LUNMF US	Lawson Winder, CFA
	MP Materials	MP	MP US	Lawson Winder, CFA
	New Gold Inc.	YNGD	NGD CN	Lawson Winder, CFA
	New Gold Inc.	NGD	NGD US	Lawson Winder, CFA
	Newmont Corporation	NEM	NEM US	Lawson Winder, CFA
	Newmont Corporation	XNCRF	NEM AU	Lawson Winder, CFA
	Nucor	NUE	NUE US	Lawson Winder, CFA
	Pan American Silver	PAAS	PAAS US	Lawson Winder, CFA
	Steel Dynamics	STLD	STLD US	Lawson Winder, CFA
	Teck Resources	YTECK	TECK/B CN	Lawson Winder, CFA
	Teck Resources Ltd	TECK	TECK US	Lawson Winder, CFA
	Triple Flag Precious Metals Corp.	YTFPM	TFPM CN	Lawson Winder, CFA
	Triple Flag Precious Metals Corp.	TFPM	TFPM US	Lawson Winder, CFA
	Wheaton Precious Metals	WPM	WPM US	Lawson Winder, CFA

## NEUTRAL

	Barrick Gold	GOLD	GOLD US	Lawson Winder, CFA
	Cleveland-Cliffs	CLF	CLF US	Lawson Winder, CFA
	First Quantum	FQVLF	FQVLF US	Lawson Winder, CFA
	First Quantum Minerals	YFM	FM CN	Lawson Winder, CFA
	Franco-Nevada	YFNV	FNV CN	Lawson Winder, CFA
	Franco-Nevada	FNV	FNV US	Lawson Winder, CFA
	Reliance, Inc.	RS	RS US	Lawson Winder, CFA
	United States Steel Corporation	X	X US	Lawson Winder, CFA

## UNDERPERFORM

	B2Gold Corp	YBTO	BTO CN	Lawson Winder, CFA
	B2Gold Corp	BTG	BTG US	Lawson Winder, CFA
	Centerra Gold	YCG	CG CN	Lawson Winder, CFA
	Centerra Gold	CGAU	CGAU US	Lawson Winder, CFA
	Eldorado Gold	EGO	EGO US	Lawson Winder, CFA
	Eldorado Gold	YELD	ELD CN	Lawson Winder, CFA
	Nexa Resources	NEXA	NEXA US	Lawson Winder, CFA
	Royal Gold	RGLD	RGLD US	Lawson Winder, CFA
	SSR Mining Inc.	SSRM	SSRM US	Lawson Winder, CFA
	SSR Mining Inc.	YSSRM	SSRM CN	Lawson Winder, CFA

## US - Healthcare Technology &amp; Distribution Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
<b>BUY</b>	Cardinal Health	CAH	CAH US	Allen Lutz, CFA
	CVS Health	CVS	CVS US	Allen Lutz, CFA
	Definitive Healthcare Corp	DH	DH US	Allen Lutz, CFA
	dentalcorp	YDNTL	DNTL CN	Allen Lutz, CFA
	Envista	NVST	NVST US	Allen Lutz, CFA
	HealthEquity Inc	HQY	HQY US	Allen Lutz, CFA
	Henry Schein	HSIC	HSIC US	Allen Lutz, CFA
	McKesson	MCK	MCK US	Allen Lutz, CFA
	Progyny	PGNY	PGNY US	Allen Lutz, CFA
	Waystar	WAY	WAY US	Allen Lutz, CFA

## NEUTRAL

	Cencora Inc	COR	COR US	Allen Lutz, CFA
	Dentsply Sirona, Inc.	XRAY	XRAY US	Allen Lutz, CFA
	Doximity Inc	DOCS	DOCS US	Allen Lutz, CFA



**US - Healthcare Technology & Distribution Coverage Cluster**

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
	Omniceil Inc.	OMCL	OMCL US	Allen Lutz, CFA
	Teladoc Health	TDOC	TDOC US	Allen Lutz, CFA

**UNDERPERFORM**

	GoodRx	GDRX	GDRX US	Allen Lutz, CFA
	Hims & Hers	HIMS	HIMS US	Allen Lutz, CFA
	Owens & Minor	OMI	OMI US	Allen Lutz, CFA
	Premier, Inc.	PINC	PINC US	Allen Lutz, CFA

**North America - Banks Coverage Cluster**

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
<b>BUY</b>				
	Ally Financial	ALLY	ALLY US	Brandon Berman
	Ares Capital Corporation	ARCC	ARCC US	Derek Hewett
	Barings BDC Inc	BBDC	BBDC US	Derek Hewett
	Blackstone Secured Lending Fund	BXSL	BXSL US	Derek Hewett
	Blue Owl Capital Corporation	OBDC	OBDC US	Derek Hewett
	BNY	BK	BK US	Ebrahim H. Poonawala
	Canadian Imperial Bank of Commerce	CM	CM US	Ebrahim H. Poonawala
	Canadian Imperial Bank of Commerce	YCM	CM CN	Ebrahim H. Poonawala
	Citigroup Inc.	C	C US	Ebrahim H. Poonawala
	Compass Diversified Holdings	CODI	CODI US	Derek Hewett
	Crescent Capital BDC	CCAP	CCAP US	Derek Hewett
	Cullen/Frost Bankers Inc	CFR	CFR US	Ebrahim H. Poonawala
	East West Bancorp, Incorporated	EWBC	EWBC US	Ebrahim H. Poonawala
	Fifth Third Bank	FITB	FITB US	Ebrahim H. Poonawala
	First Bancorp Puerto Rico	FBP	FBP US	Brandon Berman
	First Horizon Corporation	FHN	FHN US	Ebrahim H. Poonawala
	FNB Corporation	FNB	FNB US	Brandon Berman
	Goldman Sachs	GS	GS US	Ebrahim H. Poonawala
	Golub Capital BDC, Inc.	GBDC	GBDC US	Derek Hewett
	Huntington Bancshares Inc.	HBAN	HBAN US	Ebrahim H. Poonawala
	JPMorgan Chase & Co.	JPM	JPM US	Ebrahim H. Poonawala
	Kayne Anderson BDC, Inc.	KBDC	KBDC US	Derek Hewett
	KeyCorp	KEY	KEY US	Ebrahim H. Poonawala
	M&T Bank	MTB	MTB US	Ebrahim H. Poonawala
	Morgan Stanley	MS	MS US	Ebrahim H. Poonawala
	National Bank of Canada	YNA	NA CN	Ebrahim H. Poonawala
	New Mountain Finance Corporation	NMFC	NMFC US	Derek Hewett
	Northern Trust Corporation	NTRS	NTRS US	Ebrahim H. Poonawala
	Nuveen Churchill Direct Lending	NCDL	NCDL US	Derek Hewett
	Royal Bank of Canada	RY	RY US	Ebrahim H. Poonawala
	Royal Bank of Canada	YRY	RY CN	Ebrahim H. Poonawala
	Safehold, Inc	SAFE	SAFE US	Derek Hewett
	Sixth Street Specialty Lending, Inc	TSIX	TSIX US	Derek Hewett
	Synovus Financial Corp.	SNV	SNV US	Ebrahim H. Poonawala
	Texas Capital Bancshares Inc.	TCBI	TCBI US	Brandon Berman
	The PNC Financial Services Group, Inc.	PNC	PNC US	Ebrahim H. Poonawala
	Toronto-Dominion Bank	TD	TD US	Ebrahim H. Poonawala
	Toronto-Dominion Bank	YTD	TD CN	Ebrahim H. Poonawala
	Truist Financial	TFC	TFC US	Ebrahim H. Poonawala
	U.S. Bancorp	USB	USB US	Ebrahim H. Poonawala
	Webster Financial Corp.	WBS	WBS US	Brandon Berman
	Wells Fargo & Company	WFC	WFC US	Ebrahim H. Poonawala
	Western Alliance Bancorp	WAL	WAL US	Ebrahim H. Poonawala

**NEUTRAL**

	AGNC Investment Corp	AGNC	AGNC US	Derek Hewett
	Annaly Capital Management	NLY	NLY US	Derek Hewett
	Associated Banc-Corp	ASB	ASB US	Brandon Berman
	Bain Capital Specialty Finance, Inc.	BCSF	BCSF US	Derek Hewett
	Bank of Montreal	BMO	BMO US	Ebrahim H. Poonawala
	Bank of Montreal	YBMO	BMO CN	Ebrahim H. Poonawala



## North America - Banks Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
	Bank of Nova Scotia	YBNS	BNS CN	Ebrahim H. Poonawala
	Bank of Nova Scotia	BNS	BNS US	Ebrahim H. Poonawala
	Blackstone Mortgage Trust Inc	BXMT	BXMT US	Derek Hewett
	Citizens Financial Group	CFG	CFG US	Ebrahim H. Poonawala
	Commerce Bancshares Inc.	CBSH	CBSH US	Brandon Berman
	Flagstar Financial Inc	FLG	FLG US	Ebrahim H. Poonawala
	Goldman Sachs BDC, Inc.	GSBD	GSBD US	Derek Hewett
	Ladder Capital Corp	LADR	LADR US	Derek Hewett
	Palmer Square Capital BDC	PSBD	PSBD US	Derek Hewett
	PennyMac Mortgage Investment Trust	PMT	PMT US	Derek Hewett
	Popular Inc	BPOP	BPOP US	Brandon Berman
	Prosperity Bancshares Inc	PB	PB US	Ebrahim H. Poonawala
	Regions Financial	RF	RF US	Ebrahim H. Poonawala
	Runway Growth	RWAY	RWAY US	Derek Hewett
	Starwood Property Trust	STWD	STWD US	Derek Hewett

## UNDERPERFORM

	Apollo Commercial Real Estate Finance	ARI	ARI US	Derek Hewett
	Ares Commercial Real Estate Corporation	ACRE	ACRE US	Derek Hewett
	Bank of Hawaii Corp.	BOH	BOH US	Brandon Berman
	BrightSpire Capital Inc.	BRSP	BRSP US	Derek Hewett
	Carlyle Secured Lending Inc	CGBD	CGBD US	Derek Hewett
	Comerica Incorporated	CMA	CMA US	Brandon Berman
	First Hawaiian Inc.	FHB	FHB US	Brandon Berman
	Guild Holdings Company	GHLD	GHLD US	Derek Hewett
	Invesco Mortgage Capital, Inc.	IVR	IVR US	Derek Hewett
	loanDepot Inc	LDI	LDI US	Derek Hewett
	MidCap Financial Investment Co	MFIC	MFIC US	Derek Hewett
	State Street Corporation	STT	STT US	Ebrahim H. Poonawala
	TPG RE Finance Trust, Inc.	TRTX	TRTX US	Derek Hewett
	Zions Bancorp	ZION	ZION US	Brandon Berman

## US - Insurance Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
<b>BUY</b>				
	Aflac	AFL	AFL US	Joshua Shanker
	Allstate Corp.	ALL	ALL US	Joshua Shanker
	Arch Capital	ACGL	ACGL US	Joshua Shanker
	Axis Capital	AXS	AXS US	Joshua Shanker
	Baldwin Insurance Group Inc	BWIN	BWIN US	Joshua Shanker
	Cincinnati Financial Corporation	CINF	CINF US	Joshua Shanker
	Corebridge Financial	CRBG	CRBG US	Joshua Shanker
	Everest Group Ltd	EG	EG US	Joshua Shanker
	MetLife	MET	MET US	Joshua Shanker
	Progressive	PGR	PGR US	Joshua Shanker
	RenaissanceRe	RNR	RNR US	Joshua Shanker
	Ryan Specialty Holdings Inc	RYAN	RYAN US	Joshua Shanker
	Trupanion	TRUP	TRUP US	Joshua Shanker
	W.R. Berkley	WRB	WRB US	Joshua Shanker

## NEUTRAL

	American International Group	AIG	AIG US	Joshua Shanker
	Brown & Brown	BRO	BRO US	Joshua Shanker
	Lincoln National	LNC	LNC US	Joshua Shanker
	Marsh McLennan	MMC	MMC US	Joshua Shanker
	Principal Financial Group	PFG	PFG US	Joshua Shanker
	Prudential Financial	PRU	PRU US	Joshua Shanker
	The Hartford	HIG	HIG US	Joshua Shanker
	Unum	UNM	UNM US	Joshua Shanker
	Willis Towers Watson	WTW	WTW US	Joshua Shanker

## UNDERPERFORM

	Aon	AON	AON US	Joshua Shanker
--	-----	-----	--------	----------------



**US - Insurance Coverage Cluster**

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
	Chubb Ltd	CB	CB US	Joshua Shanker
	CNA Financial	CNA	CNA US	Joshua Shanker
	Goosehead Insurance Inc.	GSHD	GSHD US	Joshua Shanker
	Travelers Cos	TRV	TRV US	Joshua Shanker
	Voya	VOYA	VOYA US	Joshua Shanker

**RVW**

	Arthur J. Gallagher & Co.	AJG	AJG US	Joshua Shanker
	Assurant	AIZ	AIZ US	Grace Carter, CFA
	Intact Financial	YIFC	IFC CN	Grace Carter, CFA
	Intact Financial	IFCZF	IFCZF US	Grace Carter, CFA
	Selective	SIGI	SIGI US	Grace Carter, CFA
	The Hanover	THG	THG US	Grace Carter, CFA

**US - Biopharmaceuticals Coverage Cluster**

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
-------------------	---------	-------------	------------------	---------

**BUY**

	89bio, Inc	ETNB	ETNB US	Jason Zemansky
	Aardvark Therapeutics	AARD	AARD US	Tim Anderson
	Acumen Pharma	ABOS	ABOS US	Jason Zemansky
	Agiros Pharmaceuticals	AGIO	AGIO US	Alec W. Stranahan
	Akero Therapeutics	AKRO	AKRO US	Jason Zemansky
	Amylyx Pharmaceuticals	AMLX	AMLX US	Tim Anderson
	Apogee Therapeutics	APGE	APGE US	Tim Anderson
	Beam Therapeutics	BEAM	BEAM US	Alec W. Stranahan
	BridgeBio Pharma	BBIO	BBIO US	Jason Zemansky
	Candel Therapeutics	CADL	CADL US	Alec W. Stranahan
	Caribou	CRBU	CRBU US	Alec W. Stranahan
	CG Oncology	CGON	CGON US	Alec W. Stranahan
	CRISPR Therapeutics	CRSP	CRSP US	Alec W. Stranahan
	Day One Biopharmaceuticals	DAWN	DAWN US	Alec W. Stranahan
	Eli Lilly	LLY	LLY US	Tim Anderson
	Erasca	ERAS	ERAS US	Alec W. Stranahan
	Gilead Sciences Inc.	GILD	GILD US	Tim Anderson
	HUTCHMED	HCM	HCM US	Alec W. Stranahan
	Immatics	IMTX	IMTX US	Alec W. Stranahan
	Insmid Incorporated	INSM	INSM US	Jason Zemansky
	Intellia Therapeutics	NTLA	NTLA US	Alec W. Stranahan
	Janux Therapeutics	JANX	JANX US	Alec W. Stranahan
	Keros	KROS	KROS US	Jason Zemansky
	Krystal Biotech	KRYS	KRYS US	Alec W. Stranahan
	Kura Oncology	KURA	KURA US	Jason Zemansky
	MeiraGTx	MGTX	MGTX US	Alec W. Stranahan
	Merck	MRK	MRK US	Tim Anderson
	Metsera	MTSR	MTSR US	Tim Anderson
	Mineralys Therapeutics	MLYS	MLYS US	Tim Anderson
	Regenxbio, Inc.	RGNX	RGNX US	Alec W. Stranahan
	Revolution Medicines	RVMD	RVMD US	Alec W. Stranahan
	Rocket Pharmaceuticals, Inc.	RCKT	RCKT US	Jason Zemansky
	Sana Biotechnology	SANA	SANA US	Alec W. Stranahan
	SpringWorks	SWTX	SWTX US	Alec W. Stranahan
	Syndax Pharmaceuticals	SNDX	SNDX US	Jason Zemansky
	Traverse Therapeutics Inc	TVTX	TVTX US	Jason Zemansky
	Tyra Biosciences	TYRA	TYRA US	Jason Zemansky
	Werewolf Therapeutics	HOWL	HOWL US	Jason Zemansky
	Xencor	XNCR	XNCR US	Alec W. Stranahan

**NEUTRAL**

	AbbVie	ABBV	ABBV US	Tim Anderson
	Arcus Biosciences	RCUS	RCUS US	Jason Zemansky
	Biogen Inc.	BIIB	BIIB US	Tim Anderson
	Bristol-Myers Squibb	BMJ	BMJ US	Tim Anderson
	Cytokinetics, Incorporated	CYTK	CYTK US	Jason Zemansky



**US - Biopharmaceuticals Coverage Cluster**

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
	IGM Biosciences	IGMS	IGMS US	Tim Anderson
	Johnson & Johnson	JNJ	JNJ US	Tim Anderson
	Novavax	NVAX	NVAX US	Alec W. Stranahan
	Perspective Therapeutics	CATX	CATX US	Alec W. Stranahan
	Pfizer	PFE	PFE US	Tim Anderson
	Recursion Pharmaceuticals, Inc.	RXRX	RXRX US	Alec W. Stranahan
	Vir	VIR	VIR US	Alec W. Stranahan
	Y-mAbs Therapeutics, Inc	YMAB	YMAB US	Alec W. Stranahan
<b>UNDERPERFORM</b>				
	Alector, Inc	ALEC	ALEC US	Alec W. Stranahan
	Amgen Inc.	AMGN	AMGN US	Tim Anderson
	BioXcel Therapeutics	BTAI	BTAI US	Alec W. Stranahan
	CureVac	CVAC	CVAC US	Alec W. Stranahan
	Editas Medicine	EDIT	EDIT US	Alec W. Stranahan
	Esperion	ESPR	ESPR US	Jason Zemansky
	Lyell Immunopharma	LYEL	LYEL US	Jason Zemansky
	Madrigal Pharmaceuticals	MDGL	MDGL US	Jason Zemansky
	Moderna	MRNA	MRNA US	Tim Anderson
	Regeneron Pharmaceuticals Inc.	REGN	REGN US	Tim Anderson
	TG Therapeutics	TGTX	TGTX US	Alec W. Stranahan

**North America – Integrated Oil, Refining & Midstream Coverage Cluster**

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
<b>BUY</b>				
	Cheniere Energy Inc	LNG	LNG US	Jean Ann Salisbury
	Chevron Corporation	CVX	CVX US	Jean Ann Salisbury
	DT Midstream Inc	DTM	DTM US	Jean Ann Salisbury
	Energy Transfer LP	ET	ET US	Jean Ann Salisbury
	Enterprise Products Partners, L.P.	EPD	EPD US	Jean Ann Salisbury
	Kinder Morgan Inc	KMI	KMI US	Jean Ann Salisbury
	Kinetik Holdings Inc.	KNTK	KNTK US	Jean Ann Salisbury
	Kodiak Gas Services, Inc.	KGS	KGS US	Jean Ann Salisbury
	ONEOK Inc	OKE	OKE US	Jean Ann Salisbury
	Phillips 66	PSX	PSX US	Jean Ann Salisbury
	Targa Resources Corp.	TRGP	TRGP US	Jean Ann Salisbury
	The Williams Companies, Inc.	WMB	WMB US	Jean Ann Salisbury
	Venture Global	VG	VG US	Jean Ann Salisbury
<b>NEUTRAL</b>				
	ExxonMobil Corp.	XOM	XOM US	Jean Ann Salisbury
	Marathon Petroleum Corporation	MPC	MPC US	Jean Ann Salisbury
	Occidental Petroleum	OXY	OXY US	Jean Ann Salisbury
	Plains All American Pipeline, L.P.	PAA	PAA US	Jean Ann Salisbury
	Plains GP Holdings, L.P.	PAGP	PAGP US	Jean Ann Salisbury
	Suncor	YSU	SU CN	Jean Ann Salisbury
	Suncor	SU	SU US	Jean Ann Salisbury
	Valero Energy Corp.	VLO	VLO US	Jean Ann Salisbury
<b>UNDERPERFORM</b>				
	Cheniere Energy Partners	CQP	CQP US	Jean Ann Salisbury
	Delek Logistics Partners LP	DKL	DKL US	Jean Ann Salisbury
	Delek US Holdings	DK	DK US	Jean Ann Salisbury
	MPLX LP	MPLX	MPLX US	Jean Ann Salisbury
	PBF Energy	PBF	PBF US	Jean Ann Salisbury
	Western Midstream Partners, LP	WES	WES US	Jean Ann Salisbury



# Disclosures

## Important Disclosures

### Equity Investment Rating Distribution: Energy Group (as of 31 Mar 2025)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	88	61.97%	Buy	63	71.59%
Hold	30	21.13%	Hold	26	86.67%
Sell	24	16.90%	Sell	18	75.00%

### Equity Investment Rating Distribution: Financial Services Group (as of 31 Mar 2025)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	157	56.47%	Buy	108	68.79%
Hold	65	23.38%	Hold	46	70.77%
Sell	56	20.14%	Sell	31	55.36%

### Equity Investment Rating Distribution: Health Care Group (as of 31 Mar 2025)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	226	59.16%	Buy	128	56.64%
Hold	82	21.47%	Hold	36	43.90%
Sell	74	19.37%	Sell	30	40.54%

### Equity Investment Rating Distribution: Industrials/Multi-Industry Group (as of 31 Mar 2025)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	52	56.52%	Buy	25	48.08%
Hold	17	18.48%	Hold	11	64.71%
Sell	23	25.00%	Sell	10	43.48%

### Equity Investment Rating Distribution: Media & Entertainment Group (as of 31 Mar 2025)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	28	49.12%	Buy	15	53.57%
Hold	15	26.32%	Hold	9	60.00%
Sell	14	24.56%	Sell	8	57.14%

### Equity Investment Rating Distribution: Non-Ferrous Metals/Mining & Minerals Group (as of 31 Mar 2025)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	61	58.65%	Buy	29	47.54%
Hold	22	21.15%	Hold	10	45.45%
Sell	21	20.19%	Sell	10	47.62%

### Equity Investment Rating Distribution: Retailing Group (as of 31 Mar 2025)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	77	53.47%	Buy	33	42.86%
Hold	29	20.14%	Hold	18	62.07%
Sell	38	26.39%	Sell	15	39.47%

### Equity Investment Rating Distribution: Textiles/Apparel Group (as of 31 Mar 2025)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	13	54.17%	Buy	7	53.85%
Hold	7	29.17%	Hold	6	85.71%
Sell	4	16.67%	Sell	2	50.00%

### Equity Investment Rating Distribution: Global Group (as of 31 Mar 2025)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	1867	54.40%	Buy	1108	59.35%
Hold	774	22.55%	Hold	466	60.21%
Sell	791	23.05%	Sell	368	46.52%

<sup>R1</sup> Issuers that were investment banking clients of BofA Securities or one of its affiliates within the past 12 months. For purposes of this Investment Rating Distribution, the coverage universe includes only stocks. A stock rated Neutral is included as a Hold, and a stock rated Underperform is included as a Sell.





**FUNDAMENTAL EQUITY OPINION KEY:** Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. **VOLATILITY RISK RATINGS**, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. **INVESTMENT RATINGS** reflect the analyst's assessment of both a stock's absolute total return potential as well as its attractiveness for investment relative to other stocks within its Coverage Cluster (defined below). Our investment ratings are: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperform stocks are the least attractive stocks in a coverage cluster. An investment rating of 6 (No Rating) indicates that a stock is no longer trading on the basis of fundamentals. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).

Investment rating	Total return expectation (within 12-month period of date of initial rating)	Ratings dispersion guidelines for coverage cluster <sup>R2</sup>
Buy	≥ 10%	≤ 70%
Neutral	≥ 0%	≤ 30%
Underperform	N/A	≥ 20%

<sup>R2</sup>Ratings dispersions may vary from time to time where BofA Global Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

**INCOME RATINGS**, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividend. *Coverage Cluster* is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofA Global Research report referencing the stock.

Price Charts for the securities referenced in this research report are available on the [Price Charts website](#), or call 1-800-MERRILL to have them mailed.

One or more analysts contributing to this report owns stock of the covered issuer: Agnico-Eagle, AMETEK Inc, Eli Lilly, Goldman Sachs, Trade Desk, Inc.

BofAS or one of its affiliates acts as a market maker for the equity securities recommended in the report: Agnico Eagle, AMETEK, Bath & Body Works, Eli Lilly, Energy Transfer LP, Goldman Sachs, Hims & Hers, Ralph Lauren, RenaissanceRe, The Trade Desk.

BofAS or an affiliate was a manager of a public offering of securities of this issuer within the last 12 months: Eli Lilly, Energy Transfer LP.

The issuer is or was, within the last 12 months, an investment banking client of BofAS and/or one or more of its affiliates: Agnico-Eagle, Bath & Body Works, Eli Lilly, Energy Transfer LP, Goldman Sachs, Ralph Lauren, Renaissance Re.

BofAS or an affiliate has received compensation from the issuer for non-investment banking services or products within the past 12 months: Agnico-Eagle, AMETEK Inc, Bath & Body Works, Eli Lilly, Energy Transfer LP, Goldman Sachs, Hims & Hers, Ralph Lauren, Renaissance Re, Trade Desk, Inc.

The issuer is or was, within the last 12 months, a non-securities business client of BofAS and/or one or more of its affiliates: Agnico-Eagle, AMETEK Inc, Bath & Body Works, Eli Lilly, Energy Transfer LP, Goldman Sachs, Hims & Hers, Ralph Lauren.

BofAS or an affiliate has received compensation for investment banking services from this issuer within the past 12 months: Bath & Body Works, Eli Lilly, Energy Transfer LP, Goldman Sachs, Renaissance Re.

BofAS or an affiliate expects to receive or intends to seek compensation for investment banking services from this issuer or an affiliate of the issuer within the next three months: Agnico-Eagle, Bath & Body Works, Eli Lilly, Energy Transfer LP, Goldman Sachs, Ralph Lauren.

BofAS together with its affiliates beneficially owns one percent or more of the common stock of this issuer. If this report was issued on or after the 9th day of the month, it reflects the ownership position on the last day of the previous month. Reports issued before the 9th day of a month reflect the ownership position at the end of the second month preceding the date of the report: Agnico-Eagle, Bath & Body Works, Eli Lilly, Energy Transfer LP, Goldman Sachs, Renaissance Re, Trade Desk, Inc.

BofAS or one of its affiliates is willing to sell to, or buy from, clients the common equity of the issuer on a principal basis: Agnico Eagle, AMETEK, Bath & Body Works, Eli Lilly, Energy Transfer LP, Goldman Sachs, Hims & Hers, Ralph Lauren, RenaissanceRe, The Trade Desk.

The issuer is or was, within the last 12 months, a securities business client (non-investment banking) of BofAS and/or one or more of its affiliates: Agnico-Eagle, AMETEK Inc, Bath & Body Works, Eli Lilly, Energy Transfer LP, Goldman Sachs, Hims & Hers, Ralph Lauren, Renaissance Re, Trade Desk, Inc.

BofA Global Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking. The analyst(s) responsible for this report may also receive compensation based upon, among other factors, the overall profitability of the Bank's sales and trading businesses relating to the class of securities or financial instruments for which such analyst is responsible.

## Other Important Disclosures

One or more Canada-based analysts contributing to this report has visited the material operations of the issuer within the last 12 months: Agnico-Eagle.

From time to time research analysts conduct site visits of covered issuers. BofA Global Research policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits.

Prices are indicative and for information purposes only. Except as otherwise stated in the report, for any recommendation in relation to an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report and in relation to a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.

Recipients who are not institutional investors or market professionals should seek the advice of their independent financial advisor before considering information in this report in connection with any investment decision, or for a necessary explanation of its contents.

Officers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.

Refer to [BofA Global Research policies relating to conflicts of interest](#).

**"BofA Securities" includes BofA Securities, Inc. ("BofAS") and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. "BofA Securities" is a global brand for BofA Global Research.**

**Information relating to Non-US affiliates of BofA Securities and Distribution of Affiliate Research Reports:**

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers (AMF). BofA Securities Europe SA ("BofASE") with registered address at 51, rue La Boétie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code Monétaire et Financier (Monetary and Financial Code), BofASE is an établissement de crédit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers. BofASE's share capital can be found at [www.bofam.com/BofASEdisclaimer](http://www.bofam.com/BofASEdisclaimer); BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company,



Frankfurt Branch regulated by BaFin, the ECB and the CBI; BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en España, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch Equities (Australia) Limited, regulated by the Australian Securities and Investments Commission; Merrill Lynch (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSF); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Canadian Investment Regulatory Organization; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch Israel Limited, regulated by Israel Securities Authority; Merrill Lynch (DIFC): Merrill Lynch International (DIFC Branch), regulated by the Dubai Financial Services Authority (DFSA); Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de Títulos e Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority. This information has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSF; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India by BofAS India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to 'Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information prepared and issued by Merrill Lynch (DIFC) is done so in accordance with the requirements of the DFSA conduct of business rules. BofA Europe (Frankfurt) distributes this information in Germany and is regulated by BaFin, the ECB and the CBI. BofA Securities entities, including BofA Europe and BofASE (France), may outsource/delegate the marketing and/or provision of certain research services or aspects of research services to other branches or members of the BofA Securities group. You may be contacted by a different BofA Securities entity acting for and on behalf of your service provider where permitted by applicable law. This does not change your service provider. Please refer to the [Electronic Communications Disclaimers](#) for further information.

This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.

#### General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.

Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the issuer or the market that is anticipated to have a short-term price impact on the equity securities of the issuer. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

BofAS or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information.

In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.

#### Copyright and General Information:

Copyright 2025 Bank of America Corporation. All rights reserved. iQdatabase® is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. This document and its content is provided solely for informational purposes and cannot be used for training or developing artificial intelligence (AI) models or as an input in any AI application (collectively, an AI tool). Any attempt to utilize this document or any of its content in connection with an AI tool without explicit written permission from BofA Global Research is strictly prohibited. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities.



Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving issuers mentioned in this material is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of BofA Securities in connection with the legal proceedings or matters relevant to such proceedings.

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

Any information relating to sustainability in this material is limited as discussed herein and is not intended to provide a comprehensive view on any sustainability claim with respect to any issuer or security.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Securities policy-related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.



# Research Analysts

---

**Andrew Obin**

Research Analyst  
BofAS  
[andrew.obin@bofa.com](mailto:andrew.obin@bofa.com)

**Lorraine Hutchinson, CFA**

Research Analyst  
BofAS  
[lorraine.hutchinson@bofa.com](mailto:lorraine.hutchinson@bofa.com)

**Lawson Winder, CFA >>**

Research Analyst  
Merrill Lynch (Canada)  
[lawson.winder@bofa.com](mailto:lawson.winder@bofa.com)

**Tim Anderson**

Research Analyst  
BofAS  
[tim.m.anderson@bofa.com](mailto:tim.m.anderson@bofa.com)

**Jean Ann Salisbury**

Research Analyst  
BofAS  
[jeanann.salisbury@bofa.com](mailto:jeanann.salisbury@bofa.com)

**Ebrahim H. Poonawala**

Research Analyst  
BofAS  
[ebrahim.poonawala@bofa.com](mailto:ebrahim.poonawala@bofa.com)

**Christopher Nardone**

Research Analyst  
BofAS  
[christopher.nardone@bofa.com](mailto:christopher.nardone@bofa.com)

**Joshua Shanker**

Research Analyst  
BofAS  
[joshua.shanker@bofa.com](mailto:joshua.shanker@bofa.com)

**Jessica Reif Ehrlich**

Research Analyst  
BofAS  
[jessica.reif@bofa.com](mailto:jessica.reif@bofa.com)

**Allen Lutz, CFA**

Research Analyst  
BofAS  
[allen.lutz@bofa.com](mailto:allen.lutz@bofa.com)

**Thomas (T.J.) Thornton**

Head of Research Marketing  
BofAS  
[thomas.thornton2@bofa.com](mailto:thomas.thornton2@bofa.com)

**Nathan Zibilich, CFA**

Research Analyst  
BofAS  
[nathan.zibilich@bofa.com](mailto:nathan.zibilich@bofa.com)

**Derek Harris**

Portfolio Strategist  
BofAS  
[derek.harris@bofa.com](mailto:derek.harris@bofa.com)

Trading ideas and investment strategies discussed herein may give rise to significant risk and are not suitable for all investors. Investors should have experience in relevant markets and the financial resources to absorb any losses arising from applying these ideas or strategies.

>> Employed by a non-US affiliate of BofAS and is not registered/qualified as a research analyst under the FINRA rules. Refer to "Other Important Disclosures" for information on certain BofA Securities entities that take responsibility for the information herein in particular jurisdictions.